首页> 美国卫生研究院文献>PLoS Clinical Trials >Validation of World Health Organisation HIV/AIDS Clinical Staging in Predicting Initiation of Antiretroviral Therapy and Clinical Predictors of Low CD4 Cell Count in Uganda
【2h】

Validation of World Health Organisation HIV/AIDS Clinical Staging in Predicting Initiation of Antiretroviral Therapy and Clinical Predictors of Low CD4 Cell Count in Uganda

机译:世界卫生组织艾滋病毒/艾滋病临床分期在预测抗逆转录病毒疗法的启动和乌干达CD4细胞计数低的临床预测因素中的有效性

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

IntroductionThe WHO clinical guidelines for HIV/AIDS are widely used in resource limited settings to represent the gold standard of CD4 counts for antiviral therapy initiation. The utility of the WHO-defined stage 1 and 2 clinical factors used in WHO HIV/AIDS clinical staging in predicting low CD4 cell count has not been established in Uganda. Although the WHO staging has shown low sensitivity for predicting CD4<200cells/mm3, it has not been evaluated at for CD4 cut-offs of <250cells/mm3 or <350 cells/mm3.
机译:简介WHO的HIV / AIDS临床指南在资源有限的环境中广泛使用,代表了抗病毒治疗启动CD4计数的金标准。乌干达尚未确定在WHO HIV / AIDS临床分期中使用WHO定义的1期和2期临床因素来预测CD4细胞计数低的效用。尽管WHO分期显示出对CD4 <200cells / mm 3 的预测灵敏度较低,但尚未评估CD4阈值<250cells / mm 3 或< 350个/ mm 3

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号